GOSS Gossamer Bio Inc
Company Analysis
Latest News
🔴 Gossamer Bio falls 5.4% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Gossamer Bio is trading 5.3% down today amid continued volatility following its 1-for-80 reverse stock split
Gossamer Bio is trading at $10.16 (5.3% down) as the stock experiences ongoing volatility following its 1-for-80 reverse stock split. • The reverse split...
🔴 Gossamer Bio is trading 5.55% down today after a 1-for-80 reverse stock split
Gossamer Bio is trading at $10.76, down 5.55%, after its 1-for-80 reverse stock split became effective at 11:59 p.m. ET on September 10, 2026. - Every 80...
Gossamer Bio Effects 1-for-80 Reverse Stock Split to Regain Nasdaq Compliance
Gossamer Bio, Inc. has implemented a 1-for-80 reverse stock split of its common stock, which became effective at 11:59 p.m. ET on September 10, 2026. The...
Gossamer Bio's 1-for-80 Reverse Split Keeps Nasdaq Hopes Alive, but Can a Shrinking Biotech Survive on $57 Million and One Drug?
Shares plunged 10.5% to $0.14 on September 10 as Gossamer Bio executed one of the most aggressive reverse stock splits in recent biotech memory — an 80-to-1...
🔴 Gossamer Bio is trading 11% down today after board selected 1-for-80 reverse split
Gossamer Bio is trading 10.52% down now at $0.14 after its board selected a 1-for-80 reverse stock split to regain compliance with Nasdaq’s minimum bid-price...
🔴 Gossamer Bio is trading 6% down in pre-market after board selected a 1-for-80 reverse split
Gossamer Bio is trading 6.01% down now at $0.15 after its board selected a 1-for-80 reverse stock split to regain compliance with Nasdaq’s minimum bid-price...
Gossamer Bio triggers 1-for-80 reverse split, aiming for Nasdaq compliance
Gossamer Bio’s board of directors approved a 1-for-80 reverse stock split of its common stock. The company intends to increase its per-share trading price to...
🔴 Gossamer Bio is trading 16.34% down today — cause remains unclear
Gossamer Bio is trading 16.34% down at $0.15, based on the provided live-market price; no clear company-specific catalyst has been identified for September 9,...
🔴 Gossamer Bio is trading 18% down in pre-market — No clear company-specific catalyst identified
Gossamer Bio is trading 18% down at $0.15, with no clear company-specific catalyst emerging for September 9, 2026. - Scheduled to present at the Cantor Global...
🔴 Gossamer Bio is trading 5.04% down today amid dilution concerns from its August 21 placement
Gossamer Bio is trading 5.04% down now at $0.16, with investor concerns focused on financing-related dilution despite broader biotechnology and major U.S....
🔴 Gossamer Bio is trading 5.29% down today amid a 4.24% biotech sector ETF decline
Gossamer Bio is trading 5.29% down now at $0.16 after broader biotech weakness. - The biotech sector ETF is down 4.24%, making sector pressure the clearest...
🟢 Gossamer Bio is trading 5.53% up today
Gossamer Bio is trading at $0.18, up 5.53%, with no clear company-specific catalyst identified. - No company-specific announcement dated August 31, 2026 was...
H.C. Wainwright Reaffirms 'Buy' Rating for Gossamer Bio Amid NDA Progress for Seralutinib
H.C. Wainwright reiterates a "Buy" rating and a $2.00 price target for Gossamer Bio Inc. shares. Gossamer prepares to submit a New Drug Application (NDA) for...
🟢 Gossamer Bio is trading 7.02% up in pre-market with no confirmed overnight catalyst
Gossamer Bio is trading at $0.19 (+7.02%) in pre-market, with the move appearing speculative or liquidity-driven. - No new August 27, 2026 company-specific...
Gossamer Bio's $250 Million Lifeline Comes at a Steep Price — Can an FDA Bet Justify the Dilution?
Shares slid 10.3% to $0.18 on August 26, bucking a strong biotech tape (XBI up 2.06%), as investors took a harder look at the massive dilution embedded in...
🔴 Gossamer Bio is trading 10.61% down today after investors reassessed dilution risk
Gossamer Bio is trading 10.61% down now at $0.18 as investors reassess dilution risk from its structured private placement. - Financing includes pre-funded...
🔴 Gossamer Bio is trading 9.7% down today amid dilution and financing-overhang concerns
Gossamer Bio is trading 9.7% down at $0.18 as investors appeared to reassess dilution and financing overhang from its recently announced structured private...